Recently several panels of physicians, researchers, regulators and individuals with diabetes who are experts in continuous glucose monitoring (CGM) technologies addressed the issue how to move beyond the HbA1c measurement as the sole marker of glycemic control. Although HbA1c has proved extremely valuable in for patient management, is a valuable measure of population health and remains a validated indicator of glycation as a risk factor for complications, it is not as helpful for personalized diabetes management. The recently published ATTD consensus recommendations represent the current understanding of how CGM results can affect outcomes. CGM, either from real-time use (rtCGM) or intermittently-viewed continuous glucose monitoring (iCGM), address many of the limitations inherent in HbA1c testing and SMBG. The reliable identification of hypoglycemia is just as important as the measurement …
